increased carcinoma incidence_Cdkn2a<tm1Cjs>/Cdkn2a<+>

http://metadb.riken.jp/0002038I129X1SvJC57BL6NIHOlaHsdCdkn2atm1CjsCdkn2aCdkn2aCdkn2atm1Cjs

increased carcinoma incidence_Cdkn2a<tm1Cjs>/Cdkn2a<+>

表現型アノテーション

MGI marker

http://metadb.riken.jp/db/mgi_rdf/variant_of

• cyclin-dependent kinase inhibitor 2A
  http://metadb.riken.jp/db/mgi_rdf/MGI:104738

遺伝子型

http://metadb.riken.jp/db/mgi_rdf/allele_composition

• Cdkn2a<tm1Cjs>/Cdkn2a<+>

アレルシンボル

http://metadb.riken.jp/db/mgi_rdf/allele_symbol

• Cdkn2a<+>|Cdkn2a<tm1Cjs>

遺伝的背景

http://metadb.riken.jp/db/mgi_rdf/genetic_background

• involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd

MP annotation

http://metadb.riken.jp/db/bioresource_schema/brs_indicatesPhenotype

• increased carcinoma incidence
  http://purl.obolibrary.org/obo/MP_0002038

文献

http://purl.org/net/cito/citesAsAuthority

• Karen S. Kelly-Spratt, et.al., p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways., PLoS biology, 2004, 2
  http://rdf.ncbi.nlm.nih.gov/pubmed/15314658